Evaluation of the clinical value of a simple flowmeter in the management of male lower urinary tract symptoms

Study Type – Diagnostic (exploratory cohort) Level of Evidence 3b What's known on the subject? and What does the study add? Electronic uroflowmetry reasonably predicts the likelihood of bladder outlet obstruction (BOO) and risk of AUR. This low‐cost device, Uflowmeter™, allows men to perform ur...

Full description

Saved in:
Bibliographic Details
Published inBJU international Vol. 109; no. 11; pp. 1690 - 1696
Main Authors Chan, Chi‐Kwok, Yip, Sidney Kam‐Hung, Wu, Irene P.H., Li, Miu‐Ling, Chan, Ning‐Hong
Format Journal Article
LanguageEnglish
Published Oxford, UK Blackwell Publishing Ltd 01.06.2012
Wiley-Blackwell
Wiley Subscription Services, Inc
Subjects
Online AccessGet full text
ISSN1464-4096
1464-410X
1464-410X
DOI10.1111/j.1464-410X.2011.10581.x

Cover

Abstract Study Type – Diagnostic (exploratory cohort) Level of Evidence 3b What's known on the subject? and What does the study add? Electronic uroflowmetry reasonably predicts the likelihood of bladder outlet obstruction (BOO) and risk of AUR. This low‐cost device, Uflowmeter™, allows men to perform uroflowmetry at home with ease and the results are compatible with that of electronic uroflowmentry. It can also estimates risk of AUR and the need for TURP to relieve LUTS. OBJECTIVE •  To show the clinical value of a simple flowmeter, which has been devised to measure uroflow on an ordinal scale (<10, 10–15, 15–19 and >19 mL/s) at home, for the management of male lower urinary tract symptoms (LUTS). PATIENTS AND METHODS •  A total of 186 men with LUTS were enrolled in the study. •  The mean (range) follow‐up was 220 (68–431) days. The men's mean (range) age was 65.5 (46–83) years, mean (range) maximum urinary flow rate (Qmax) 12.8 (4.3–39.5) mL/s, mean (range) voided volume 294.8 (151–686) mL; mean (range) postvoid residual urine volume (PVR) 50 (0–303) mL and mean (range) International Prostate Symptom Score (IPSS) 13.5 (1–31). •  The men underwent electronic uroflowmetry (‘clinic uroflowmetry’) and completed an IPSS questionnaire in the clinic. They then conducted 10 measurements with the device at home (‘home uroflowetry’). The uroflowmetry and IPSS questionnaire were repeated 2 weeks later. •  Quadratically weighted Kappa analysis (κ) of the home uroflowmetry vs. clinic uroflowmetry, and of the sensitivity and specificity of the home uroflowmetry values to correspond to the mean Qmax of clinic uroflowmetry (<10, 10–15, 15–19 and >19 mL/s) was performed. Similar analyses were performed for the IPSS. •  Kaplan–Meier analysis was performed to evaluate whether home uroflowmetry was able to prognosticate acute urinary retention (AUR) or the need for transurethral resection of the prostate (TURP). RESULTS •  The home uroflowmetry values (κ= 0.84, 95% confidence interval [CI]: 0.78–0.90) were superior to the IPSS (κ= 0.083; 95% CI: 0–0.173) in correlating with the mean Qmax of clinic uroflowmetry. •  Home uroflowmetry was most sensitive in identifying a mean Qmax of >19 mL/s (sensitivity: 0.99; 95% CI:0.97–1.00) and most specific in identifying a mean Qmax of <10 mL/s (specificity: 0.90; 95% CI:0.83–0.94). •  The home uroflowmetry works best in ruling out a mean Qmax of <19 mL/s (diagnostic odds ratio [DOR]= 349.3; 95% CI:40.24–3037.7), followed by a mean Qmax of <15 mL/s (DOR = 91.02; 95% CI:31.23–265.23) and a mean Qmax of <10 mL/s (DOR = 32.04; 95% CI:14.0–73.19). •  Men with a home uroflowmetry value ≤10 mL/s were more likely (n= 6; 8.8%) than those with a home uroflowmetry value >10 mL/s (n= 2; 1.7%) to develop AUR or require TURP (log‐rank test: P= 0.017; hazard ratio:5.61(95% CI:1.10–28.64)). The IPSS failed to display the same discriminative capability. CONCLUSION •  Home uroflowmetry using this simple device is a satisfactory estimation of clinic uroflowmetry using an electronic flowmeter and can predict the significant progression of male LUTS.
AbstractList Study Type – Diagnostic (exploratory cohort) Level of Evidence 3b What's known on the subject? and What does the study add? Electronic uroflowmetry reasonably predicts the likelihood of bladder outlet obstruction (BOO) and risk of AUR. This low‐cost device, Uflowmeter™, allows men to perform uroflowmetry at home with ease and the results are compatible with that of electronic uroflowmentry. It can also estimates risk of AUR and the need for TURP to relieve LUTS. OBJECTIVE •  To show the clinical value of a simple flowmeter, which has been devised to measure uroflow on an ordinal scale (<10, 10–15, 15–19 and >19 mL/s) at home, for the management of male lower urinary tract symptoms (LUTS). PATIENTS AND METHODS •  A total of 186 men with LUTS were enrolled in the study. •  The mean (range) follow‐up was 220 (68–431) days. The men's mean (range) age was 65.5 (46–83) years, mean (range) maximum urinary flow rate (Qmax) 12.8 (4.3–39.5) mL/s, mean (range) voided volume 294.8 (151–686) mL; mean (range) postvoid residual urine volume (PVR) 50 (0–303) mL and mean (range) International Prostate Symptom Score (IPSS) 13.5 (1–31). •  The men underwent electronic uroflowmetry (‘clinic uroflowmetry’) and completed an IPSS questionnaire in the clinic. They then conducted 10 measurements with the device at home (‘home uroflowetry’). The uroflowmetry and IPSS questionnaire were repeated 2 weeks later. •  Quadratically weighted Kappa analysis (κ) of the home uroflowmetry vs. clinic uroflowmetry, and of the sensitivity and specificity of the home uroflowmetry values to correspond to the mean Qmax of clinic uroflowmetry (<10, 10–15, 15–19 and >19 mL/s) was performed. Similar analyses were performed for the IPSS. •  Kaplan–Meier analysis was performed to evaluate whether home uroflowmetry was able to prognosticate acute urinary retention (AUR) or the need for transurethral resection of the prostate (TURP). RESULTS •  The home uroflowmetry values (κ= 0.84, 95% confidence interval [CI]: 0.78–0.90) were superior to the IPSS (κ= 0.083; 95% CI: 0–0.173) in correlating with the mean Qmax of clinic uroflowmetry. •  Home uroflowmetry was most sensitive in identifying a mean Qmax of >19 mL/s (sensitivity: 0.99; 95% CI:0.97–1.00) and most specific in identifying a mean Qmax of <10 mL/s (specificity: 0.90; 95% CI:0.83–0.94). •  The home uroflowmetry works best in ruling out a mean Qmax of <19 mL/s (diagnostic odds ratio [DOR]= 349.3; 95% CI:40.24–3037.7), followed by a mean Qmax of <15 mL/s (DOR = 91.02; 95% CI:31.23–265.23) and a mean Qmax of <10 mL/s (DOR = 32.04; 95% CI:14.0–73.19). •  Men with a home uroflowmetry value ≤10 mL/s were more likely (n= 6; 8.8%) than those with a home uroflowmetry value >10 mL/s (n= 2; 1.7%) to develop AUR or require TURP (log‐rank test: P= 0.017; hazard ratio:5.61(95% CI:1.10–28.64)). The IPSS failed to display the same discriminative capability. CONCLUSION •  Home uroflowmetry using this simple device is a satisfactory estimation of clinic uroflowmetry using an electronic flowmeter and can predict the significant progression of male LUTS.
Study Type - Diagnostic (exploratory cohort) Level of Evidence 3b What's known on the subject? and What does the study add? Electronic uroflowmetry reasonably predicts the likelihood of bladder outlet obstruction (BOO) and risk of AUR. This low-cost device, Uflowmeter(™) , allows men to perform uroflowmetry at home with ease and the results are compatible with that of electronic uroflowmentry. It can also estimates risk of AUR and the need for TURP to relieve LUTS.UNLABELLEDStudy Type - Diagnostic (exploratory cohort) Level of Evidence 3b What's known on the subject? and What does the study add? Electronic uroflowmetry reasonably predicts the likelihood of bladder outlet obstruction (BOO) and risk of AUR. This low-cost device, Uflowmeter(™) , allows men to perform uroflowmetry at home with ease and the results are compatible with that of electronic uroflowmentry. It can also estimates risk of AUR and the need for TURP to relieve LUTS.To show the clinical value of a simple flowmeter, which has been devised to measure uroflow on an ordinal scale (<10, 10-15, 15-19 and >19 mL/s) at home, for the management of male lower urinary tract symptoms (LUTS).OBJECTIVETo show the clinical value of a simple flowmeter, which has been devised to measure uroflow on an ordinal scale (<10, 10-15, 15-19 and >19 mL/s) at home, for the management of male lower urinary tract symptoms (LUTS).A total of 186 men with LUTS were enrolled in the study. The mean (range) follow-up was 220 (68-431) days. The men's mean (range) age was 65.5 (46-83) years, mean (range) maximum urinary flow rate (Qmax) 12.8 (4.3-39.5) mL/s, mean (range) voided volume 294.8 (151-686) mL; mean (range) postvoid residual urine volume (PVR) 50 (0-303) mL and mean (range) International Prostate Symptom Score (IPSS) 13.5 (1-31). The men underwent electronic uroflowmetry ('clinic uroflowmetry') and completed an IPSS questionnaire in the clinic. They then conducted 10 measurements with the device at home ('home uroflowetry'). The uroflowmetry and IPSS questionnaire were repeated 2 weeks later. Quadratically weighted Kappa analysis (κ) of the home uroflowmetry vs. clinic uroflowmetry, and of the sensitivity and specificity of the home uroflowmetry values to correspond to the mean Qmax of clinic uroflowmetry (<10, 10-15, 15-19 and >19 mL/s) was performed. Similar analyses were performed for the IPSS. Kaplan-Meier analysis was performed to evaluate whether home uroflowmetry was able to prognosticate acute urinary retention (AUR) or the need for transurethral resection of the prostate (TURP).PATIENTS AND METHODSA total of 186 men with LUTS were enrolled in the study. The mean (range) follow-up was 220 (68-431) days. The men's mean (range) age was 65.5 (46-83) years, mean (range) maximum urinary flow rate (Qmax) 12.8 (4.3-39.5) mL/s, mean (range) voided volume 294.8 (151-686) mL; mean (range) postvoid residual urine volume (PVR) 50 (0-303) mL and mean (range) International Prostate Symptom Score (IPSS) 13.5 (1-31). The men underwent electronic uroflowmetry ('clinic uroflowmetry') and completed an IPSS questionnaire in the clinic. They then conducted 10 measurements with the device at home ('home uroflowetry'). The uroflowmetry and IPSS questionnaire were repeated 2 weeks later. Quadratically weighted Kappa analysis (κ) of the home uroflowmetry vs. clinic uroflowmetry, and of the sensitivity and specificity of the home uroflowmetry values to correspond to the mean Qmax of clinic uroflowmetry (<10, 10-15, 15-19 and >19 mL/s) was performed. Similar analyses were performed for the IPSS. Kaplan-Meier analysis was performed to evaluate whether home uroflowmetry was able to prognosticate acute urinary retention (AUR) or the need for transurethral resection of the prostate (TURP).The home uroflowmetry values (κ= 0.84, 95% confidence interval [CI]: 0.78-0.90) were superior to the IPSS (κ= 0.083; 95% CI: 0-0.173) in correlating with the mean Qmax of clinic uroflowmetry. Home uroflowmetry was most sensitive in identifying a mean Qmax of >19 mL/s (sensitivity: 0.99; 95% CI:0.97-1.00) and most specific in identifying a mean Qmax of <10 mL/s (specificity: 0.90; 95% CI:0.83-0.94). The home uroflowmetry works best in ruling out a mean Qmax of <19 mL/s (diagnostic odds ratio [DOR]= 349.3; 95% CI:40.24-3037.7), followed by a mean Qmax of <15 mL/s (DOR = 91.02; 95% CI:31.23-265.23) and a mean Qmax of <10 mL/s (DOR = 32.04; 95% CI:14.0-73.19). Men with a home uroflowmetry value ≤10 mL/s were more likely (n= 6; 8.8%) than those with a home uroflowmetry value >10 mL/s (n= 2; 1.7%) to develop AUR or require TURP (log-rank test: P= 0.017; hazard ratio:5.61(95% CI:1.10-28.64)). The IPSS failed to display the same discriminative capability.RESULTSThe home uroflowmetry values (κ= 0.84, 95% confidence interval [CI]: 0.78-0.90) were superior to the IPSS (κ= 0.083; 95% CI: 0-0.173) in correlating with the mean Qmax of clinic uroflowmetry. Home uroflowmetry was most sensitive in identifying a mean Qmax of >19 mL/s (sensitivity: 0.99; 95% CI:0.97-1.00) and most specific in identifying a mean Qmax of <10 mL/s (specificity: 0.90; 95% CI:0.83-0.94). The home uroflowmetry works best in ruling out a mean Qmax of <19 mL/s (diagnostic odds ratio [DOR]= 349.3; 95% CI:40.24-3037.7), followed by a mean Qmax of <15 mL/s (DOR = 91.02; 95% CI:31.23-265.23) and a mean Qmax of <10 mL/s (DOR = 32.04; 95% CI:14.0-73.19). Men with a home uroflowmetry value ≤10 mL/s were more likely (n= 6; 8.8%) than those with a home uroflowmetry value >10 mL/s (n= 2; 1.7%) to develop AUR or require TURP (log-rank test: P= 0.017; hazard ratio:5.61(95% CI:1.10-28.64)). The IPSS failed to display the same discriminative capability.Home uroflowmetry using this simple device is a satisfactory estimation of clinic uroflowmetry using an electronic flowmeter and can predict the significant progression of male LUTS.CONCLUSIONHome uroflowmetry using this simple device is a satisfactory estimation of clinic uroflowmetry using an electronic flowmeter and can predict the significant progression of male LUTS.
Study Type - Diagnostic (exploratory cohort) Level of Evidence3b What's known on the subject? and What does the study add? Electronic uroflowmetry reasonably predicts the likelihood of bladder outlet obstruction (BOO) and risk of AUR. This low-cost device, Uflowmeter(TM), allows men to perform uroflowmetry at home with ease and the results are compatible with that of electronic uroflowmentry. It can also estimates risk of AUR and the need for TURP to relieve LUTS. OBJECTIVE * To show the clinical value of a simple flowmeter, which has been devised to measure uroflow on an ordinal scale (<10, 10-15, 15-19 and >19mL/s) at home, for the management of male lower urinary tract symptoms (LUTS). PATIENTS AND METHODS * A total of 186 men with LUTS were enrolled in the study. * The mean (range) follow-up was 220 (68-431) days. The men's mean (range) age was 65.5 (46-83) years, mean (range) maximum urinary flow rate (Qmax) 12.8 (4.3-39.5) mL/s, mean (range) voided volume 294.8 (151-686) mL; mean (range) postvoid residual urine volume (PVR) 50 (0-303) mL and mean (range) International Prostate Symptom Score (IPSS) 13.5 (1-31). * The men underwent electronic uroflowmetry ('clinic uroflowmetry') and completed an IPSS questionnaire in the clinic. They then conducted 10 measurements with the device at home ('home uroflowetry'). The uroflowmetry and IPSS questionnaire were repeated 2 weeks later. * Quadratically weighted Kappa analysis ([kappa]) of the home uroflowmetry vs. clinic uroflowmetry, and of the sensitivity and specificity of the home uroflowmetry values to correspond to the mean Qmax of clinic uroflowmetry (<10, 10-15, 15-19 and >19mL/s) was performed. Similar analyses were performed for the IPSS. * Kaplan-Meier analysis was performed to evaluate whether home uroflowmetry was able to prognosticate acute urinary retention (AUR) or the need for transurethral resection of the prostate (TURP). RESULTS * The home uroflowmetry values ([kappa]= 0.84, 95% confidence interval [CI]: 0.78-0.90) were superior to the IPSS ([kappa]= 0.083; 95% CI: 0-0.173) in correlating with the mean Qmax of clinic uroflowmetry. * Home uroflowmetry was most sensitive in identifying a mean Qmax of >19mL/s (sensitivity: 0.99; 95% CI:0.97-1.00) and most specific in identifying a mean Qmax of <10mL/s (specificity: 0.90; 95% CI:0.83-0.94). * The home uroflowmetry works best in ruling out a mean Qmax of <19mL/s (diagnostic odds ratio [DOR]= 349.3; 95% CI:40.24-3037.7), followed by a mean Qmax of <15mL/s (DOR = 91.02; 95% CI:31.23-265.23) and a mean Qmax of <10mL/s (DOR = 32.04; 95% CI:14.0-73.19). * Men with a home uroflowmetry value ≤10mL/s were more likely (n= 6; 8.8%) than those with a home uroflowmetry value >10mL/s (n= 2; 1.7%) to develop AUR or require TURP (log-rank test: P= 0.017; hazard ratio:5.61(95% CI:1.10-28.64)). The IPSS failed to display the same discriminative capability. CONCLUSION * Home uroflowmetry using this simple device is a satisfactory estimation of clinic uroflowmetry using an electronic flowmeter and can predict the significant progression of male LUTS. [PUBLICATION ABSTRACT]
Study Type - Diagnostic (exploratory cohort) Level of Evidence 3b What's known on the subject? and What does the study add? Electronic uroflowmetry reasonably predicts the likelihood of bladder outlet obstruction (BOO) and risk of AUR. This low-cost device, Uflowmeter(™) , allows men to perform uroflowmetry at home with ease and the results are compatible with that of electronic uroflowmentry. It can also estimates risk of AUR and the need for TURP to relieve LUTS. To show the clinical value of a simple flowmeter, which has been devised to measure uroflow on an ordinal scale (<10, 10-15, 15-19 and >19 mL/s) at home, for the management of male lower urinary tract symptoms (LUTS). A total of 186 men with LUTS were enrolled in the study. The mean (range) follow-up was 220 (68-431) days. The men's mean (range) age was 65.5 (46-83) years, mean (range) maximum urinary flow rate (Qmax) 12.8 (4.3-39.5) mL/s, mean (range) voided volume 294.8 (151-686) mL; mean (range) postvoid residual urine volume (PVR) 50 (0-303) mL and mean (range) International Prostate Symptom Score (IPSS) 13.5 (1-31). The men underwent electronic uroflowmetry ('clinic uroflowmetry') and completed an IPSS questionnaire in the clinic. They then conducted 10 measurements with the device at home ('home uroflowetry'). The uroflowmetry and IPSS questionnaire were repeated 2 weeks later. Quadratically weighted Kappa analysis (κ) of the home uroflowmetry vs. clinic uroflowmetry, and of the sensitivity and specificity of the home uroflowmetry values to correspond to the mean Qmax of clinic uroflowmetry (<10, 10-15, 15-19 and >19 mL/s) was performed. Similar analyses were performed for the IPSS. Kaplan-Meier analysis was performed to evaluate whether home uroflowmetry was able to prognosticate acute urinary retention (AUR) or the need for transurethral resection of the prostate (TURP). The home uroflowmetry values (κ= 0.84, 95% confidence interval [CI]: 0.78-0.90) were superior to the IPSS (κ= 0.083; 95% CI: 0-0.173) in correlating with the mean Qmax of clinic uroflowmetry. Home uroflowmetry was most sensitive in identifying a mean Qmax of >19 mL/s (sensitivity: 0.99; 95% CI:0.97-1.00) and most specific in identifying a mean Qmax of <10 mL/s (specificity: 0.90; 95% CI:0.83-0.94). The home uroflowmetry works best in ruling out a mean Qmax of <19 mL/s (diagnostic odds ratio [DOR]= 349.3; 95% CI:40.24-3037.7), followed by a mean Qmax of <15 mL/s (DOR = 91.02; 95% CI:31.23-265.23) and a mean Qmax of <10 mL/s (DOR = 32.04; 95% CI:14.0-73.19). Men with a home uroflowmetry value ≤10 mL/s were more likely (n= 6; 8.8%) than those with a home uroflowmetry value >10 mL/s (n= 2; 1.7%) to develop AUR or require TURP (log-rank test: P= 0.017; hazard ratio:5.61(95% CI:1.10-28.64)). The IPSS failed to display the same discriminative capability. Home uroflowmetry using this simple device is a satisfactory estimation of clinic uroflowmetry using an electronic flowmeter and can predict the significant progression of male LUTS.
Author Chan, Ning‐Hong
Wu, Irene P.H.
Li, Miu‐Ling
Chan, Chi‐Kwok
Yip, Sidney Kam‐Hung
Author_xml – sequence: 1
  givenname: Chi‐Kwok
  surname: Chan
  fullname: Chan, Chi‐Kwok
– sequence: 2
  givenname: Sidney Kam‐Hung
  surname: Yip
  fullname: Yip, Sidney Kam‐Hung
– sequence: 3
  givenname: Irene P.H.
  surname: Wu
  fullname: Wu, Irene P.H.
– sequence: 4
  givenname: Miu‐Ling
  surname: Li
  fullname: Li, Miu‐Ling
– sequence: 5
  givenname: Ning‐Hong
  surname: Chan
  fullname: Chan, Ning‐Hong
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25918768$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/21933332$$D View this record in MEDLINE/PubMed
BookMark eNqNkcFuGyEQhlGVqEmcvkKFVFXqxRtYljVcKrVR2qSK1Esj5YYwHlosYF1gm_jtyzp2K-WUuTBivhmG_z9DR3GIgBCmpKE1LtYN7fpu3lFy37SE0oYSLmjz-Aqd_iscHXIi-xN0lvOakHrR89fopKWS1WhPUbj6o_2oixsiHiwuvwAb76Iz2uOpAtOtxtmFjQds_fAQoEDCLu7YoKP-CQFimbigK1ORWh-TizptcUnaFJy3YVOGkM_RsdU-w5v9OUN3X65-XF7Pb79_vbn8dDs3XSvoHCi3ZEE0W5meStsaA0QK2WrLDXRES24YE0JSIyxbUC1JJ_iCL8Eu5arlnM3Qh6e5mzT8HiEXFVw24L2OMIxZ0aqZ4GTSYIbePUPXw5hi3U5RxhnrJG8n6u2eGpcBVmqTXKjfUwchK_B-D-hctbNJR-Pyf45LKha9qNzHJ86kIecEVhlXdvJXpZyvm6nJYbVWk3lqMlJNDqudw-qxDhDPBhzeeEHr_u0H52H74j71-dvdLmV_ASNuvNw
CODEN BJINFO
CitedBy_id crossref_primary_10_1007_s00345_019_02907_3
crossref_primary_10_1007_s40846_018_0375_0
crossref_primary_10_1016_j_urology_2020_08_027
crossref_primary_10_1097_MOU_0b013e32835bb149
crossref_primary_10_1136_bmjopen_2021_056234
crossref_primary_10_1007_s00120_017_0547_5
crossref_primary_10_1016_j_jpurol_2024_07_007
crossref_primary_10_4081_aiua_2022_2_169
crossref_primary_10_1016_j_fjurol_2024_102846
crossref_primary_10_1007_s11255_014_0733_y
crossref_primary_10_1007_s41973_020_00103_0
crossref_primary_10_1016_j_purol_2022_07_142
Cites_doi 10.1111/j.1464-410X.1993.tb00684.x
10.1016/j.jclinepi.2004.12.009
10.1046/j.1464-410X.1996.00097.x
10.1016/S1569-9056(04)90343-0
10.1002/(SICI)1520-6777(1999)18:1<25::AID-NAU5>3.0.CO;2-O
10.1016/S0090-4295(01)01298-5
10.1002/nau.20383
10.1046/j.1464-410X.1996.00115.x
10.1037/1082-989X.1.2.150
10.5489/cuaj.09092
10.1016/S0022-5347(17)38458-6
10.4103/0970-1591.32058
10.1002/(SICI)1520-6777(1999)18:3<183::AID-NAU4>3.0.CO;2-I
10.1016/j.eursup.2009.02.001
10.1016/S0022-5347(17)35482-4
10.1016/j.eururo.2006.09.019
10.1016/j.eursup.2009.02.002
10.1016/S0094-0143(21)00966-6
10.1016/S0895-4356(03)00177-X
10.1016/j.urology.2006.03.035
10.1056/NEJMoa030656
10.1136/emj.20.5.453
10.1097/00042307-200007000-00008
10.1093/ptj/85.3.257
10.1016/S0022-5347(01)64508-7
10.1136/bmj.296.6627.965
10.1007/BF00182666
10.1136/bmj.298.6667.156
10.1016/S0022-5347(05)68271-7
10.1111/j.1464-410X.1976.tb06719.x
ContentType Journal Article
Copyright 2011 THE AUTHORS. BJU INTERNATIONAL © 2011 BJU INTERNATIONAL
2015 INIST-CNRS
2011 THE AUTHORS. BJU INTERNATIONAL © 2011 BJU INTERNATIONAL.
Copyright_xml – notice: 2011 THE AUTHORS. BJU INTERNATIONAL © 2011 BJU INTERNATIONAL
– notice: 2015 INIST-CNRS
– notice: 2011 THE AUTHORS. BJU INTERNATIONAL © 2011 BJU INTERNATIONAL.
DBID AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7QP
7X8
DOI 10.1111/j.1464-410X.2011.10581.x
DatabaseName CrossRef
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Calcium & Calcified Tissue Abstracts
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Calcium & Calcified Tissue Abstracts
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic
Calcium & Calcified Tissue Abstracts
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1464-410X
EndPage 1696
ExternalDocumentID 2975456781
21933332
25918768
10_1111_j_1464_410X_2011_10581_x
BJU10581
Genre article
Research Support, Non-U.S. Gov't
Controlled Clinical Trial
Journal Article
GroupedDBID ---
.3N
.55
.GA
.Y3
05W
0R~
10A
1OB
1OC
23N
2WC
31~
33P
36B
3O-
3SF
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5HH
5LA
5RE
5VS
66C
6P2
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHQN
AAIPD
AAMMB
AAMNL
AANLZ
AAONW
AASGY
AAXRX
AAYCA
AAZKR
ABCQN
ABCUV
ABDBF
ABEML
ABJNI
ABLJU
ABOCM
ABPVW
ABQWH
ABXGK
ACAHQ
ACCZN
ACFBH
ACGFS
ACGOF
ACMXC
ACPOU
ACPRK
ACSCC
ACUHS
ACXBN
ACXQS
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADXAS
ADZMN
AEFGJ
AEIGN
AEIMD
AENEX
AEUYR
AEYWJ
AFBPY
AFEBI
AFFNX
AFFPM
AFGKR
AFWVQ
AFZJQ
AGHNM
AGXDD
AGYGG
AHBTC
AHMBA
AIACR
AIDQK
AIDYY
AIQQE
AITYG
AIURR
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
ATUGU
AZBYB
AZVAB
BAFTC
BAWUL
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CAG
COF
CS3
D-6
D-7
D-E
D-F
DCZOG
DIK
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
E3Z
EAD
EAP
EBC
EBD
EBS
EJD
EMB
EMK
EMOBN
ESX
EX3
F00
F01
F04
F5P
FUBAC
G-S
G.N
GODZA
H.X
HF~
HGLYW
HZI
HZ~
IHE
IX1
J0M
J5H
K48
KBYEO
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
O66
O9-
OIG
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
PQQKQ
Q.N
Q11
QB0
R.K
RJQFR
ROL
RX1
SUPJJ
SV3
TEORI
TUS
UB1
V9Y
W8V
W99
WBKPD
WHWMO
WIH
WIJ
WIK
WOHZO
WOW
WQJ
WVDHM
WXI
WXSBR
X7M
XG1
YFH
ZGI
ZXP
~IA
~WT
AAYXX
CITATION
IQODW
AAHHS
ACCFJ
ADZOD
AEEZP
AEQDE
AIWBW
AJBDE
CGR
CUY
CVF
ECM
EIF
NPM
7QP
7X8
ID FETCH-LOGICAL-c4281-e15f070a3dc619f2cce09892af5ce40a95c338891c8f371a9048575befb9d2553
IEDL.DBID DR2
ISSN 1464-4096
1464-410X
IngestDate Wed Oct 01 10:00:30 EDT 2025
Sun Jul 13 04:11:36 EDT 2025
Thu Apr 03 07:09:32 EDT 2025
Mon Jul 21 09:15:06 EDT 2025
Thu Apr 24 22:52:30 EDT 2025
Wed Oct 01 04:28:51 EDT 2025
Sun Sep 21 06:23:46 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 11
Keywords Evaluation
Nephrology
Urinary system disease
Male
Urinary tract disease
LUTS
Uflow-meter
Urology
Voiding dysfunction
Sensitivity
Specificity
diagnostic odds ratio
Clinical management
uroflowmetry
Ratio
Diagnosis
Lower urinary tract symptoms
Language English
License CC BY 4.0
2011 THE AUTHORS. BJU INTERNATIONAL © 2011 BJU INTERNATIONAL.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4281-e15f070a3dc619f2cce09892af5ce40a95c338891c8f371a9048575befb9d2553
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 14
content type line 23
PMID 21933332
PQID 1353349523
PQPubID 1026371
PageCount 7
ParticipantIDs proquest_miscellaneous_1011850333
proquest_journals_1353349523
pubmed_primary_21933332
pascalfrancis_primary_25918768
crossref_citationtrail_10_1111_j_1464_410X_2011_10581_x
crossref_primary_10_1111_j_1464_410X_2011_10581_x
wiley_primary_10_1111_j_1464_410X_2011_10581_x_BJU10581
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate June 2012
PublicationDateYYYYMMDD 2012-06-01
PublicationDate_xml – month: 06
  year: 2012
  text: June 2012
PublicationDecade 2010
PublicationPlace Oxford, UK
PublicationPlace_xml – name: Oxford, UK
– name: Oxford
– name: England
– name: Edgecliff
PublicationTitle BJU international
PublicationTitleAlternate BJU Int
PublicationYear 2012
Publisher Blackwell Publishing Ltd
Wiley-Blackwell
Wiley Subscription Services, Inc
Publisher_xml – name: Blackwell Publishing Ltd
– name: Wiley-Blackwell
– name: Wiley Subscription Services, Inc
References 1997; 158
2006; 50
2010; 14
1990; 17
1995; 13
1989; 298
2005; 85
2004; 3
1999; 162
1991
1976; 48
1996; 78
1996; 77
2003; 56
2003; 349
1991; 145
1993; 72
2006; 68
1999; 18
2000; 10
1993; 150
2009; 8
1996; 1
1988; 296
2010; 4
2007; 23
2001; 58
2003; 20
2007; 26
2005; 58
e_1_2_8_27_2
e_1_2_8_28_2
Chan CK (e_1_2_8_10_2) 2010; 14
e_1_2_8_29_2
Siroky MB (e_1_2_8_2_2) 1990; 17
e_1_2_8_23_2
e_1_2_8_24_2
e_1_2_8_25_2
e_1_2_8_26_2
e_1_2_8_9_2
e_1_2_8_3_2
e_1_2_8_6_2
e_1_2_8_5_2
e_1_2_8_8_2
e_1_2_8_7_2
e_1_2_8_20_2
e_1_2_8_21_2
e_1_2_8_22_2
e_1_2_8_16_2
e_1_2_8_17_2
e_1_2_8_18_2
e_1_2_8_19_2
e_1_2_8_12_2
e_1_2_8_13_2
e_1_2_8_14_2
e_1_2_8_15_2
Rollema HJ (e_1_2_8_4_2) 1991
e_1_2_8_31_2
e_1_2_8_30_2
e_1_2_8_33_2
e_1_2_8_11_2
e_1_2_8_32_2
References_xml – volume: 48
  start-page: 681
  year: 1976
  end-page: 4
  article-title: Excretion urography in the investigation of prostatism
  publication-title: Br J Urol
– volume: 3
  start-page: 88
  year: 2004
  article-title: Baseline measures as predictors of clinical progression of benign prostatic hyperplasia
  publication-title: Eur Urol Suppl
– volume: 26
  start-page: 474
  year: 2007
  end-page: 80
  article-title: Flow measurements: can several ‘wrongs’ make a ‘right’?
  publication-title: Neurourol Urodyn
– volume: 50
  start-page: 1306
  year: 2006
  end-page: 14
  article-title: Population‐based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of EPIC study
  publication-title: Eur Urol
– volume: 4
  start-page: 123
  year: 2010
  end-page: 7
  article-title: The aging male population and medical care for benign prostatic hyperplasia in Canada
  publication-title: Can Urol Assoc J
– volume: 145
  start-page: 810
  year: 1991
  end-page: 2
  article-title: Bladder outlet obstruction versus impaired detrusor contractility: the role of outflow
  publication-title: J Urol
– volume: 17
  start-page: 537
  year: 1990
  end-page: 42
  article-title: Interpretation of urinary flow rates
  publication-title: Urol Clin North Am
– volume: 349
  start-page: 2387
  year: 2003
  end-page: 98
  article-title: The long‐term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia
  publication-title: N Engl J Med
– volume: 298
  start-page: 156
  year: 1989
  end-page: 9
  article-title: Late renal failure due to prostatic outflow obstruction: a preventable disease
  publication-title: BMJ
– volume: 150
  start-page: 351
  year: 1993
  end-page: 8
  article-title: Relationship of symptoms of prostatism to commonly used physiological and anatomical measures of the severity of benign hyperplasia
  publication-title: J Urol
– volume: 72
  start-page: 181
  year: 1993
  end-page: 6
  article-title: How reliable is a single measurement of urinary flow in the diagnosis of obstruction in benign prostatic hyperplasia
  publication-title: Br J Urol
– volume: 10
  start-page: 337
  year: 2000
  end-page: 42
  article-title: The aging male: a challenge for urologists
  publication-title: Curr Opin Urol
– volume: 158
  start-page: 481
  year: 1997
  end-page: 7
  article-title: Natural history of prostatism: risk factors for acute urinary retention
  publication-title: J Urol
– volume: 296
  start-page: 965
  year: 1988
  end-page: 7
  article-title: Prostatism: how useful is routine imaging of the urinary tract?
  publication-title: Br Med J (Clin Res Ed)
– volume: 18
  start-page: 183
  year: 1999
  end-page: 91
  article-title: Low reproducibility of maximum urinary flow rate determined by portable flowmetry
  publication-title: Neurourol Urodyn
– volume: 56
  start-page: 1129
  year: 2003
  end-page: 35
  article-title: The diagnostic odds ratio: a single indicator of test performance
  publication-title: J Clin Epidemiol
– volume: 13
  start-page: 47
  year: 1995
  end-page: 58
  article-title: Analysis of bladder‐outlet function with the linearized passive urethral resistance relation, linPURR, and a disease‐specific approach for grading obstruction: from complex to simple
  publication-title: World J Urol
– volume: 14
  start-page: S23
  year: 2010
  article-title: UflowmeterTM – a simple, low‐cost and valid device to categorize different flow rates with high accuracy – an experimental laboratory verification study
  publication-title: Surg Pract
– volume: 8
  start-page: 523
  year: 2009
  end-page: 9
  article-title: Management of acute and chronic retention in men
  publication-title: Eur Urol Suppl
– volume: 78
  start-page: 385
  year: 1996
  end-page: 90
  article-title: Improved reliability of uroflowmetry investigations: results of a portable home‐based uroflowmetry study
  publication-title: Br J Urol
– volume: 1
  start-page: 150
  year: 1996
  end-page: 3
  article-title: Sample size calculations for Cohen's Kappa
  publication-title: Psychol Methods
– volume: 20
  start-page: 453
  year: 2003
  end-page: 8
  article-title: An introduction to power and sample size estimation
  publication-title: Emerg Med J
– volume: 77
  start-page: 813
  year: 1996
  end-page: 8
  article-title: The value of multiple free‐flow studies in men with lower urinary tract symptoms
  publication-title: Br J Urol
– volume: 58
  start-page: 5
  issue: 1
  year: 2001
  end-page: 16
  article-title: Natural history of benign prostatic hyperplasia
  publication-title: Urology
– volume: 58
  start-page: 859
  year: 2005
  end-page: 62
  article-title: Sample size calculation should be performed for design accuracy in diagnostic test studies
  publication-title: J Clin Epidemiol
– volume: 18
  start-page: 25
  year: 1999
  end-page: 32
  article-title: Home uroflowmetry: improved accuracy in outflow assessment
  publication-title: Neurourol Urodyn
– volume: 23
  start-page: 114
  year: 2007
  end-page: 8
  article-title: Clinical evaluation of a simple uroflowmeter for categorization of maximum urinary flow rate
  publication-title: Indian J Urol
– start-page: 201
  year: 1991
  end-page: 44
– volume: 8
  start-page: 496
  year: 2009
  end-page: 503
  article-title: Medical treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia
  publication-title: Eur Urol Suppl
– volume: 68
  start-page: 560
  year: 2006
  end-page: 4
  article-title: Epidemiologic survey of lower urinary tract symptoms in Japan
  publication-title: Urology
– volume: 85
  start-page: 257
  year: 2005
  end-page: 68
  article-title: The kappa statistic in reliability studies: use, interpretation, and sample size requirements
  publication-title: Phys Ther
– volume: 162
  start-page: 1301
  year: 1999
  end-page: 6
  article-title: Treatment for benign prostatic hyperplasia among community dwelling men: the Olmsted County study of urinary symptoms and health status
  publication-title: J Urol
– ident: e_1_2_8_3_2
  doi: 10.1111/j.1464-410X.1993.tb00684.x
– ident: e_1_2_8_15_2
  doi: 10.1016/j.jclinepi.2004.12.009
– ident: e_1_2_8_28_2
  doi: 10.1046/j.1464-410X.1996.00097.x
– volume: 14
  start-page: S23
  year: 2010
  ident: e_1_2_8_10_2
  article-title: UflowmeterTM – a simple, low‐cost and valid device to categorize different flow rates with high accuracy – an experimental laboratory verification study
  publication-title: Surg Pract
– ident: e_1_2_8_20_2
  doi: 10.1016/S1569-9056(04)90343-0
– ident: e_1_2_8_25_2
  doi: 10.1002/(SICI)1520-6777(1999)18:1<25::AID-NAU5>3.0.CO;2-O
– ident: e_1_2_8_16_2
  doi: 10.1016/S0090-4295(01)01298-5
– ident: e_1_2_8_26_2
  doi: 10.1002/nau.20383
– ident: e_1_2_8_29_2
  doi: 10.1046/j.1464-410X.1996.00115.x
– ident: e_1_2_8_12_2
  doi: 10.1037/1082-989X.1.2.150
– ident: e_1_2_8_5_2
  doi: 10.5489/cuaj.09092
– ident: e_1_2_8_33_2
  doi: 10.1016/S0022-5347(17)38458-6
– ident: e_1_2_8_13_2
  doi: 10.4103/0970-1591.32058
– ident: e_1_2_8_27_2
  doi: 10.1002/(SICI)1520-6777(1999)18:3<183::AID-NAU4>3.0.CO;2-I
– ident: e_1_2_8_18_2
  doi: 10.1016/j.eursup.2009.02.001
– ident: e_1_2_8_17_2
  doi: 10.1016/S0022-5347(17)35482-4
– ident: e_1_2_8_7_2
  doi: 10.1016/j.eururo.2006.09.019
– ident: e_1_2_8_21_2
  doi: 10.1016/j.eursup.2009.02.002
– volume: 17
  start-page: 537
  year: 1990
  ident: e_1_2_8_2_2
  article-title: Interpretation of urinary flow rates
  publication-title: Urol Clin North Am
  doi: 10.1016/S0094-0143(21)00966-6
– ident: e_1_2_8_30_2
  doi: 10.1016/S0895-4356(03)00177-X
– ident: e_1_2_8_8_2
  doi: 10.1016/j.urology.2006.03.035
– start-page: 201
  volume-title: Clinical Neurology
  year: 1991
  ident: e_1_2_8_4_2
– ident: e_1_2_8_19_2
  doi: 10.1056/NEJMoa030656
– ident: e_1_2_8_14_2
  doi: 10.1136/emj.20.5.453
– ident: e_1_2_8_6_2
  doi: 10.1097/00042307-200007000-00008
– ident: e_1_2_8_11_2
  doi: 10.1093/ptj/85.3.257
– ident: e_1_2_8_32_2
  doi: 10.1016/S0022-5347(01)64508-7
– ident: e_1_2_8_24_2
  doi: 10.1136/bmj.296.6627.965
– ident: e_1_2_8_31_2
  doi: 10.1007/BF00182666
– ident: e_1_2_8_22_2
  doi: 10.1136/bmj.298.6667.156
– ident: e_1_2_8_9_2
  doi: 10.1016/S0022-5347(05)68271-7
– ident: e_1_2_8_23_2
  doi: 10.1111/j.1464-410X.1976.tb06719.x
SSID ssj0014665
Score 2.0906749
Snippet Study Type – Diagnostic (exploratory cohort) Level of Evidence 3b What's known on the subject? and What does the study add? Electronic uroflowmetry reasonably...
Study Type - Diagnostic (exploratory cohort) Level of Evidence 3b What's known on the subject? and What does the study add? Electronic uroflowmetry reasonably...
Study Type - Diagnostic (exploratory cohort) Level of Evidence3b What's known on the subject? and What does the study add? Electronic uroflowmetry reasonably...
SourceID proquest
pubmed
pascalfrancis
crossref
wiley
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 1690
SubjectTerms Aged
Aged, 80 and over
Biological and medical sciences
Cohort Studies
Confidence intervals
diagnostic odds ratio
Equipment Design
Excretory system
Flowmeters
Humans
Lower Urinary Tract Symptoms - diagnosis
Lower Urinary Tract Symptoms - etiology
Lower Urinary Tract Symptoms - therapy
LUTS
Male
Medical sciences
Men
Middle Aged
Nephrology. Urinary tract diseases
Older people
Predictive Value of Tests
Prostatic Hyperplasia - complications
Prostatic Hyperplasia - physiopathology
Prostatic Hyperplasia - therapy
Rheology - instrumentation
Self Care - instrumentation
specificity
Uflow‐meter™ sensitivity
Urinary Bladder Neck Obstruction - diagnosis
Urinary Bladder Neck Obstruction - etiology
Urinary Bladder Neck Obstruction - therapy
Urinary system involvement in other diseases. Miscellaneous
Urinary tract. Prostate gland
Urination - physiology
Urodynamics - physiology
uroflowmetry
Urogenital system
Title Evaluation of the clinical value of a simple flowmeter in the management of male lower urinary tract symptoms
URI https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fj.1464-410X.2011.10581.x
https://www.ncbi.nlm.nih.gov/pubmed/21933332
https://www.proquest.com/docview/1353349523
https://www.proquest.com/docview/1011850333
Volume 109
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVEBS
  databaseName: Academic Search Ultimate - eBooks
  customDbUrl: https://search.ebscohost.com/login.aspx?authtype=ip,shib&custid=s3936755&profile=ehost&defaultdb=asn
  eissn: 1464-410X
  dateEnd: 20241003
  omitProxy: true
  ssIdentifier: ssj0014665
  issn: 1464-4096
  databaseCode: ABDBF
  dateStart: 19990101
  isFulltext: true
  titleUrlDefault: https://search.ebscohost.com/direct.asp?db=asn
  providerName: EBSCOhost
– providerCode: PRVBFR
  databaseName: Free Medical Journals
  customDbUrl:
  eissn: 1464-410X
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0014665
  issn: 1464-4096
  databaseCode: DIK
  dateStart: 19990101
  isFulltext: true
  titleUrlDefault: http://www.freemedicaljournals.com
  providerName: Flying Publisher
– providerCode: PRVWIB
  databaseName: Wiley Online Library - Core collection (SURFmarket)
  issn: 1464-4096
  databaseCode: DR2
  dateStart: 19970101
  customDbUrl:
  isFulltext: true
  eissn: 1464-410X
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0014665
  providerName: Wiley-Blackwell
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBYlh1IofT-2SYMKvXqxLMmWj01ICIH0ULqwN2HrASFre6m99PHrOyN5HRxyCKU-GUsj9JiRvvGMZgj57IWRmStEYgqXJ0I6lijjbJKnziopRBFX-uprfrESl2u5Hv2f8C5MjA8x_XBDyQj7NQp4Vfd3hVwkgqXrGIkTkIJiS8STjMtgsf02RZKCqiGrZCQB2D536rm3odlJ9XRb9TBpPma7uA-OztFtOJ7On5Ob_cCiV8rNcjfUS_PnTszH_zPyF-TZiGLpl8h2L8kj174ij69GO_1r0pxNQcRp5ymATLq_gkmxxOHXivbXGJuY-k33s0G3HHrdhrrN5JOD9Ro4w-gGs7lRNA1Av-mAd7to_7vZDl3TvyGr87PvpxfJmNghMaDtsMQx6WGrqbg1oL_5zBiXlqrMKi-NE2lVSgOasyqZUZ4XrCphmwFYWTtflxZ0IP6WHLRd694TmmfWAqhRHpoTzvLSW1sVEmBJzXmt8gUp9ouozRj1HJNvbPRM-xEaZ1PjbOowm_rXgrCJchsjfzyA5njGJxMhKJkMzh21IEd7xtHjZtFrTD3CQVHN-IJ8mopBzNF2U7Wu2_XoiQfIKuUc6ryLDHfbOIBweDIYa2CbB3dXn1yuwuuHf6Y8JE_gexad547IwfBj5z4CTBvq4yCAfwGx3ixg
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBYlhbYQ0nezbZqq0KsXy5Jt-dhHwjbN5lCysDdh6wEha3uJvaTNr--M5XVxyCGU-mSsGSHJM9I30miGkE9O6DiyqQh0apNAxJYFUlsTJKE1MhYi9X96fpbMFuJkGS_7dEB4F8bHhxg23FAzuvkaFRw3pG9ruQgEC5c-FCdABcmmACgf4nEdaum3n0MsKaDt8kp6HgDuY7eeO2sarVW767yBYXM-38VdgHSMb7sF6vgpWW275v1SLqebtpjqm1tRH_9T35-RvR7I0s9e8p6TB7Z6QR7N-6P6l6Q8GuKI09pRwJl0ewuTYonFrzltLjA8MXWr-rpEzxx6UXW05eCWg3QlLGN0hQndKJ4OQMNpi9e7aPO7XLd12bwii-Oj86-zoM_tEGgweFhgWexgtsm50WDCuUhrG2Yyi3IXayvCPIs1GM8yY1o6nrI8g5kGkGVhXZEZMIP4a7JT1ZXdJzSJjAFcIx1UJ6zhmTMmT2NAJgXnhUwmJN3-RaX7wOeYf2OlRgaQUDiaCkdTdaOpfk0IGzjXPvjHPXgOR4IyMIKdyWDpkRNysJUc1c8XjcLsIxxs1YhPyMehGDQdj2_yytabBp3xAFyFnAPNGy9xfysHHA5PBH3t5ObezVVfThbd69t_5vxAHs_O56fq9PvZj3fkCdBE3pfugOy0Vxv7HlBbWxx22vgHfPYwfA
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Za9wwEBYlgVAoTc900zRRoa9eLEu25cceWXI0oZQu7JuwdUDI2l5qL23z6ztjeV0c8hBK_GSsGaFjRvrGGs0Q8sEJHUc2FYFObRKI2LJAamuCJLRGxkKkfqYvLpOTuThbxIve_wnvwvj4EMMPN9SMbr1GBV8Zd1vJRSBYuPCROAEpSDYFPLktEjC2ECB9H0JJAW2XVtLzAG4fe_XcWdNoq3qyyhsYNefTXdyFR8fwttufZrvketMz75ZyPV23xVTf3Ar6-DBdf0ae9jCWfvRy95w8stULsnPRH9S_JOXxEEWc1o4CyqSbO5gUSyx-zWlzhcGJqVvWv0r0y6FXVUdbDk45SFfCJkaXmM6N4tkAtJu2eLmLNn_KVVuXzSsynx3_-HwS9JkdAg3mDgssix2sNTk3Ggw4F2ltw0xmUe5ibUWYZ7EG01lmTEvHU5ZnsM4AriysKzIDRhB_TbaqurJvCE0iYwDVSAfVCWt45ozJ0xhwScF5IZMJSTeTqHQf9hyzbyzVyPwRCkdT4WiqbjTV7wlhA-fKh_64B8_hSE4GRrAyGWw8ckIONoKj-tWiUZh7hIOlGvEJeT8Ug57j4U1e2XrdoCseQKuQc6DZ8wL3r3JA4fBE0NdObO7dXPXpbN697v835xHZ-fZlpr6eXp6_JY-BJPKOdAdkq_25tu8AsrXFYaeLfwGvEi8r
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Evaluation+of+the+clinical+value+of+a+simple+flowmeter+in+the+management+of+male+lower+urinary+tract+symptoms&rft.jtitle=BJU+international&rft.au=CHAN%2C+Chi-Kwok&rft.au=KAM-HUNG+YIP%2C+Sidney&rft.au=WU%2C+Irene+P.+H&rft.au=LI%2C+Miu-Ling&rft.date=2012-06-01&rft.pub=Wiley-Blackwell&rft.issn=1464-4096&rft.volume=109&rft.issue=11&rft.spage=1690&rft.epage=1696&rft_id=info:doi/10.1111%2Fj.1464-410X.2011.10581.x&rft.externalDBID=n%2Fa&rft.externalDocID=25918768
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1464-4096&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1464-4096&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1464-4096&client=summon